Researchers from our IBM Research labs around the world and from IBM Watson Health have contributed a total of 47 workshops, papers, posters and panels that will be presented at AMIA 2020. These contributions cover a wide range of topics but reflect our overarching goal of driving the usefulness of AI in Healthcare.
Our team of researchers based at the IBM Research-Almaden lab in California have been pursuing an ambitious challenge of building machines that can perform a preliminary read of chest X-rays provably at the level of at least entry-level radiologists.
A new AI model, developed by IBM Research and Pfizer, has used short, non-invasive and standardized speech tests to help predict the eventual onset of Alzheimer’s disease within healthy people with an accuracy of 0.7 and an AUC of 0.74 (area under the curve).
I believe one of the most promising areas for AI to make an impact is in the field of medical imaging. Through advancements in AI that allow for more intelligent and accurate analysis of video and still images, there is hope that clinicians will soon be able to widely augment the data and information they […]
In Collaboration with the National Institutes of Health, IBM Research Dives Deep into Biomarkers of Schizophrenia
In collaboration with researchers from Harvard Medical School, Mt. Sinai School of Medicine, Stanford University and the Northern California Institute for Research and Education, IBM Research is undertaking a new research initiative funded by the National Institute of Health.
What impact do measures such as shelter-in-place, mask wearing, and social distancing have on the number of COVID-19 cases? How do the COVID-19 quarantine measures that have been implemented by North American countries compare to South American countries? These are just a few questions about the wide range of non-pharmaceutical interventions (NPIs) that have been applied by governments, globally.
In 2019, IBM and the Broad Institute of MIT and Harvard started a multi-year collaborative research program to develop powerful predictive models that can potentially enable clinicians to identify patients at serious risk for cardiovascular disease (1, 2). At the start of our collaboration, we proposed an approach to develop AI-based models that combine and […]
In a new study, IBM and CHDI researchers studied the relationship between the pace of subtle cognitive decline in patients before full-fledged symptoms and their brain activity, as shown by a functional MRI. The results demonstrate that measuring the potential progression of HD could eventually be done from a single brain scan, acquired in one visit.
Our team of IBM researchers published research in Radiology around a new AI model that can predict the development of malignant breast cancer in patients within the year, at rates comparable to human radiologists.
IBM and Johns Hopkins University School of Medicine Discover Unique, Pathogenic Autoimmune Cells in Type 1 Diabetes
Researchers at JHU and IBM identify new cells involved in the autoimmune attack on insulin-producing cells in type 1 diabetes.
New continuous-flow approach to chemical synthesis holds promise in accelerating therapeutic discovery for drug-resistant infectious diseases and cancer.
New research combining the power of brain modeling, IBM’s AI, and the IBM Cloud sheds light on how brain cells interact in Huntington’s disease.